Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01239875 · ClinicalTrials.gov registry record · Early Phase 1

Vaccine Therapy With or Without Cryosurgery in Treating Patients With Residual, Relapsed, or Refractory B-Cell Non-Hodgkin Lymphoma

A Early Phase 1 study, sponsored by Mayo Clinic.

Completed
Registry status
Early Phase 1
Development phase
16
Enrollment target

NCT01239875: Completed Early Phase 1 study, sponsored by Mayo Clinic.

NCT01239875 is a Early Phase 1 study that has completed, run by Mayo Clinic. The registered enrollment target is 16 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01239875, a Early Phase 1 study, has completed, sponsored by Mayo Clinic.

COMPLETED
Registry status
Early Phase 1
Development phase
16 participants
Enrollment target

Study Summary

RATIONALE: Vaccines, such as dendritic cell therapy (DC) made from a person's tumor cells and white blood cells may help the body build an effective immune response to kill tumor cells. Cryosurgery kills cancer cells by freezing them. Giving vaccine therapy together with cryosurgery may kill more tumor cells. PURPOSE: This clinical trial studies giving vaccine therapy together with or without cryosurgery in treating patients with B-cell Non-Hodgkin's lymphoma.

Interventions

  • OTHER laboratory biomarker analysis
  • OTHER immunoenzyme technique
  • BIOLOGICAL pneumococcal polyvalent vaccine
  • PROCEDURE cryotherapy
  • BIOLOGICAL dendritic cell vaccine therapy

Trial Details

FieldValue
Enrollment Target 16 participants
Start Date 2010-11
Est. Completion 2019-07-17
Phase Early Phase 1

Sponsor

Mayo Clinic

2,844 total trials

What the Registry Record Tells You About NCT01239875

The ClinicalTrials.gov registry entry for NCT01239875 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 5 interventions - of which laboratory biomarker analysis is the first listed.

NCT01239875 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT01239875 about?

NCT01239875 is a clinical study titled "Vaccine Therapy With or Without Cryosurgery in Treating Patients With Residual, Relapsed, or Refractory B-Cell Non-Hodgkin Lymphoma". RATIONALE: Vaccines, such as dendritic cell therapy (DC) made from a person's tumor cells and white blood cells may help the body build an effective immune response to kill tumor cells. Cryosurgery kills cancer cells by freezing them. Giving vaccine therapy together with cryosurgery may kill more tu...

What is the current status of trial NCT01239875?

This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 16 participants. The study started on 2010-11. Estimated completion is 2019-07-17.

What interventions are being tested in trial NCT01239875?

The interventions under investigation include: laboratory biomarker analysis (OTHER), immunoenzyme technique (OTHER), pneumococcal polyvalent vaccine (BIOLOGICAL), cryotherapy (PROCEDURE), dendritic cell vaccine therapy (BIOLOGICAL).

Who is sponsoring clinical trial NCT01239875?

This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.